Human Genome Sciences Inc has rejected as inadequate an unsolicited takeover bid from GlaxoSmithKline Plc that is priced at $13 per share in cash. The offer values the company at approximately $2.59 billion, according to the Associated Press. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
